48 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CH
Jagiellonian University Medical College
Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.
Merck Research Laboratories
Serendipitous oxidation product of BIBN4096BS: a potent CGRP receptor antagonist.
Bristol-Myers Squibb
Identification of potent CNS-penetrant thiazolidinones as novel CGRP receptor antagonists.
Vertex Pharmaceuticals
Preparation of imidazoles as potent calcitonin gene-related peptide (CGRP) antagonists.
Bristol-Myers Squibb
[(11)C]MK-4232: The First Positron Emission Tomography Tracer for the Calcitonin Gene-Related Peptide Receptor.
Merck Research Labortories
Discovery of (R)-N-(3-(7-methyl-1H-indazol-5-yl)-1-(4-(1-methylpiperidin-4-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide (BMS-742413): a potent human CGRP antagonist with superior safety profile for the treatment of migraine through intranasal delivery.
Bristol-Myers Squibb R & D
The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.
Bristol-Myers Squibb Research & Development
Potent oxadiazole CGRP receptor antagonists for the potential treatment of migraine.
Glaxosmithkline
Discovery of (5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate (BMS-927711): an oral calcitonin gene-related peptide (CGRP) antagonist in clinical trials for treating migraine.
Bristol-Myers Squibb Research & Development
Discovery of BMS-846372, a Potent and Orally Active Human CGRP Receptor Antagonist for the Treatment of Migraine.
TBA
Design and synthesis of potent antagonists containing rigid spirocyclic privileged structures for the CGRP receptor.
Bristol-Myers Squibb R & D
The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 1.
Bristol-Myers Squibb Research & Development
MK-8825: a potent and selective CGRP receptor antagonist with good oral activity in rats.
Merck Research Laboratories
Calcitonin gene-related peptide (CGRP) receptor antagonists: pyridine as a replacement for a core amide group.
Bristol-Myers Squibb Research & Development
Calcitonin gene-related peptide (CGRP) receptor antagonists: novel aspartates and succinates.
Bristol-Myers Squibb Research & Development
Calcitonin gene-related peptide (CGRP) receptor antagonists: investigations of a pyridinone template.
Merck Research Laboratories
Orally bioavailable imidazoazepanes as calcitonin gene-related peptide (CGRP) receptor antagonists: discovery of MK-2918.
Merck Research Laboratories
Novel CGRP receptor antagonists from central amide replacements causing a reversal of preferred chirality.
Merck
Optimization of azepanone calcitonin gene-related peptide (CGRP) receptor antagonists: development of novel spiropiperidines.
Merck Research Laboratories
Novel CGRP receptor antagonists through a design strategy of target simplification with addition of molecular flexibility.
Merck
The identification of potent, orally bioavailable tricyclic CGRP receptor antagonists.
Merck Research Laboratories
Carbamates as potent calcitonin gene-related peptide antagonists with improved solution stability.
Bristol-Myers Squibb Research and Development
Discovery of (R)-4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)-N-(3-(7-methyl-1H-indazol-5-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan-2-yl)piperidine-1-carboxamide (BMS-694153): a potent antagonist of the human calcitonin gene-related peptide receptor for migraine with rapid and effic
Bristol-Myers Squibb Research & Development
Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine: discovery of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1- (2,2,2-trifluoroethyl)azepan-3-yl]-4- (2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin- 1-yl)piperidine-1-carboxamide (MK-0974).
Merck Research Laboratories
Resveratrol derivatives: Synthesis and their biological activities.
Universitat De Barcelona
Calcitonin gene-related peptide analogues with aza and indolizidinone amino acid residues reveal conformational requirements for antagonist activity at the human calcitonin gene-related peptide 1 receptor.
Université
Identification of novel, orally bioavailable spirohydantoin CGRP receptor antagonists.
Merck Research Laboratories
Benzodiazepine calcitonin gene-related peptide (CGRP) receptor antagonists: optimization of the 4-substituted piperidine.
Merck Research Laboratories
Development of human calcitonin gene-related peptide (CGRP) receptor antagonists. 1. Potent and selective small molecule CGRP antagonists. 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-l-lysyl]-4-(4-pyridinyl)piperazine: the first CGRP antagonist
Boehringer Ingelheim Pharma
Calcitonin gene-related peptide (CGRP) receptor antagonists: Heterocyclic modification of a novel azepinone lead.
Bristol-Myers Squibb
Azepino-indazoles as calcitonin gene-related peptide (CGRP) receptor antagonists.
Bristol-Myers Squibb
From micromolar to nanomolar affinity: a systematic approach to identify the binding site of CGRP at the human calcitonin gene-related peptide 1 receptor.
Eth ZüRich
Structure-activity study of hCGRP8-37, a calcitonin gene-related peptide receptor antagonist.
Université
Quinoline carboxamide and quinoline carbonitrile derivatives as mGluR2-negative allosteric modulators, compositions, and their use
Merck Sharp & Dohme
Identification and characterization of small molecule inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase.
Harvard Medical School